Showing results (121-130 of 132) with videos related to
Sort By:
Pageof 14
Plos Pathogens|May 19, 2016
Direct and Indirect Targeting of PP2A by Conserved Bacterial Type-III Effector ProteinsLin Jin, Jong Hyun Ham, Rosemary Hage, et al.Msystems|December 23, 2025
Microbial metabolites associated with healthy lifestyles in relation to metabolic syndrome and vascular health: a cross-sectional studyZhuoyu Zhang, Bingqi Ye, Jialin He, et al.Plant Biotechnology Journal|June 9, 2025
ScWRKY2: a key regulator for smut resistance in sugarcaneDongjiao Wang, Yaxin Gou, Chao Yi, et al.Journal of Environmental Management|March 17, 2020
Mobility of metal(loid)s in Pb/Zn tailings under different revegetation strategiesGuobao Wang, Wanying Zhao, Yongqiang Yuan, et al.Leukemia & Lymphoma|November 3, 2020
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)Morton Coleman, David Belada, René-Olivier Casasnovas, et al.Optics Express|October 19, 2017
Optimizing single-mode collection from pointlike sources of single photons with adaptive opticsAlexander D Hill, David Hervas, Joseph Nash, et al.Nutrition Journal|June 13, 2026
Association between food insecurity and healthy ageing: two population-based studiesQi Zhang, Jialu Yang, Yong Wang, et al.Scientific Reports|June 17, 2024
The relationship between prognosis and temporal muscle thickness in 102 patients with glioblastomaJinhai Tang, Zhenghao Dong, Lei Yang, et al.Plant Physiology|January 31, 2015
Perturbation of maize phenylpropanoid metabolism by an AvrE family type III effector from Pantoea stewartiiJo Ann E Asselin, Jinshan Lin, Alvaro L Perez-Quintero, et al.Blood Advances|December 19, 2023
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)Tycel J Phillips, Abraham Avigdor, Ronit Gurion, et al.Pageof 14